Prognostic Value of Soluble ST2 After Myocardial Infarction: A Community Perspective

American Journal of Medicine

Volumn 130, Issue 9, 2017, Pages 1112.e9-1112.e15

  Jenkins, William S ^a   Roger, Véronique L ^a   Jaffe, Allan S ^a   Weston, Susan A ^a   AbouEzzeddine, Omar F ^a   Jiang, Ruoxiang ^a   Manemann, Sheila M ^a   Enriquez Sarano, Maurice ^a  

^a MAYO CLINIC   (United States)

Author keywords

Heart failure; Mortality; Myocardial infarction; Soluble ST2

Indexed keywords

INTERLEUKIN 1 RECEPTOR; SOLUBLE SUPPRESSION OF TUMORIGENICITY 2 PROTEIN; TROPONIN T; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; IL1RL1 PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR LIKE 1 PROTEIN;

ADULT; AGED; ARTICLE; CLASSIFICATION; COMMUNITY SAMPLE; COMORBIDITY; DEATH; FEMALE; FOLLOW UP; HAZARD RATIO; HEART FAILURE; HEART INFARCTION; HUMAN; KILLIP CLASSIFICATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MINNESOTA; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; AGE DISTRIBUTION; BLOOD; CAUSE OF DEATH; COMPLICATION; DISEASE COURSE; EPIDEMIOLOGY; MORTALITY; PREDICTIVE VALUE; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SEX RATIO;

AGE DISTRIBUTION; AGED; BIOMARKERS; CAUSE OF DEATH; COMORBIDITY; DISEASE PROGRESSION; FEMALE; HEART FAILURE; HUMANS; INTERLEUKIN-1 RECEPTOR-LIKE 1 PROTEIN; MALE; MIDDLE AGED; MINNESOTA; MYOCARDIAL INFARCTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SEX DISTRIBUTION; TROPONIN T;

EID: 85018937194     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2017.02.034     Document Type: Article

References (32)

1. Mozaffarian, D., Benjamin, E.J., Go, A.S., et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation 131 (2015), e29–e322.
2. Velagaleti, R.S., Pencina, M.J., Murabito, J.M., et al. Long-term trends in the incidence of heart failure after myocardial infarction. Circulation 118 (2008), 2057–2062.
3. Roger, V.L., Weston, S.A., Gerber, Y., et al. Trends in incidence, severity, and outcome of hospitalized myocardial infarction. Circulation 121 (2010), 863–869.
4. Sabatine, M.S., Morrow, D.A., Higgins, L.J., et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation 117 (2008), 1936–1944.
5. Kohli, P., Bonaca, M.P., Kakkar, R., et al. Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. Clin Chem 58 (2012), 257–266.
6. Melton, L.J. 3rd, History of the Rochester Epidemiology Project. Mayo Clin Proc 71 (1996), 266–274.
7. St Sauver, J.L., Grossardt, B.R., Yawn, B.P., et al. Use of a medical records linkage system to enumerate a dynamic population over time: The Rochester Epidemiology Project. Am J Epidemiol 173 (2011), 1059–1068.
8. Gerber, Y., Jaffe, A.S., Weston, S.A., et al. Prognostic value of cardiac troponin T after myocardial infarction: a contemporary community experience. Mayo Clin Proc 87 (2012), 247–254.
9. Alpert, J.S., Thygesen, K., Antman, E., Bassand, J.P., Myocardial infarction redefined–a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 36 (2000), 959–969.
10. Jaffe, A.S., Elevations in cardiac troponin measurements: false false-positives: the real truth. Cardiovasc Toxicol 1 (2001), 87–92.
11. Kors, J.A., Crow, R.S., Hannan, P.J., et al. Comparison of computer-assigned Minnesota Codes with the visual standard method for new coronary heart disease events. Am J Epidemiol 151 (2000), 790–797.
12. Roger, V.L., Jacobsen, S.J., Weston, S.A., et al. Trends in the incidence and survival of patients with hospitalized myocardial infarction, Olmsted County, Minnesota, 1979 to 1994. Ann Intern Med 136 (2002), 341–348.
13. White, A.D., Folsom, A.R., Chambless, L.E., et al. Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) Study: methods and initial two years' experience. J Clin Epidemiol 49 (1996), 223–233.
14. Dieplinger, B., Januzzi, J.L. Jr., Steinmair, M., et al. Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma—the Presage ST2 assay. Clin Chim Acta 409 (2009), 33–40.
15. Broch, K., Ueland, T., Nymo, S.H., et al. Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology. Eur J Heart Fail 14 (2012), 268–277.
16. Daniels, L.B., Clopton, P., Iqbal, N., et al. Association of ST2 levels with cardiac structure and function and mortality in outpatients. Am Heart J 160 (2010), 721–728.
17. Pascual-Figal, D.A., Manzano-Fernandez, S., Boronat, M., et al. Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Fail 13 (2011), 718–725.
18. Charlson, M.E., Pompei, P., Ales, K.L., MacKenzie, C.R., A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40 (1987), 373–383.
19. Levey, A.S., Coresh, J., Greene, T., et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145 (2006), 247–254.
20. Killip, T. 3rd, Kimball, J.T., Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol 20 (1967), 457–464.
21. McKee, P.A., Castelli, W.P., McNamara, P.M., Kannel, W.B., The natural history of congestive heart failure: the Framingham study. N Engl J Med 285 (1971), 1441–1446.
22. Roger, V.L., Weston, S.A., Redfield, M.M., et al. Trends in heart failure incidence and survival in a community-based population. JAMA 292 (2004), 344–350.
23. Coglianese, E.E., Larson, M.G., Vasan, R.S., et al. Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study. Clin Chem 58 (2012), 1673–1681.
24. Vasile, V.C., Jaffe, A.S., Emerging biomarkers for acute heart conditions. Curr Opin Cardiol 29 (2014), 312–318.
25. Weinberg, E.O., Shimpo, M., De Keulenaer, G.W., et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 106 (2002), 2961–2966.
26. Pascual-Figal, D.A., Januzzi, J.L., The biology of ST2: the International ST2 Consensus Panel. Am J Cardiol 115 (2015), 3B–7B.
27. Kakkar, R., Lee, R.T., The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 7 (2008), 827–840.
28. Dhillon, O.S., Narayan, H.K., Quinn, P.A., et al. Interleukin 33 and ST2 in non-ST-elevation myocardial infarction: comparison with Global Registry of Acute Coronary Events Risk Scoring and NT-proBNP. Am Heart J 161 (2011), 1163–1170.
29. Yeh, R.W., Sidney, S., Chandra, M., et al. Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med 362 (2010), 2155–2165.
30. Roger, V.L., Cardiovascular diseases in populations: secular trends and contemporary challenges-Geoffrey Rose lecture, European Society of Cardiology meeting 2014. Eur Heart J 36 (2015), 2142–2146.
31. Smolina, K., Wright, F.L., Rayner, M., Goldacre, M.J., Determinants of the decline in mortality from acute myocardial infarction in England between 2002 and 2010: linked national database study. BMJ, 344, 2012, d8059.
32. Gerber, Y., Weston, S.A., Enriquez-Sarano, M., et al. Atherosclerotic burden and heart failure after myocardial infarction. JAMA Cardiol 1 (2016), 156–162.